SHANGHAI, Aug. 9 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. today announced shareholder resolutions adopted at its annual general meeting of shareholders held in Hong Kong on August 7, 2009.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )
At the meeting, WuXi PharmaTech shareholders approved the re-election of incumbent Class B directors Xuesong Leng, Zhaohui Zhang, and Ning Zhao, each to serve a three-year term.
In addition, the WuXi shareholders approved an amendment to the Company's Memorandum of Articles and Association that revises Article 82 so that it no longer requires a Special Resolution be obtained for an office of a Director to be considered vacated.
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .
SOURCE WuXi PharmaTech (Cayman) Inc.
CONTACT: Ronald Aldridge (for investors), Director of Investor Relations
of WuXi PharmaTech (Cayman) Inc., +1-201-585-2048, or ir@wuxiapptec.com, or
Stephanie Liu (for the media) of WuXi PharmaTech (Cayman) Inc.,
+86-21-5046-4362, or pr@wuxiapptec.com
Web site: http://www.wuxiapptec.com//
